Cognition Therapeutics Unveils Key Insights from Phase 2 Study on DLB
- Patient characteristics are consistent with other DLB studies -
PURCHASE, N.Y. — Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company focused on developing innovative drugs for neurodegenerative disorders, recently presented crucial findings regarding the participant demographics in their Phase 2 ‘SHIMMER’ study targeting mild-to-moderate dementia with Lewy bodies (DLB). This significant data was highlighted at the Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference, taking place in Madrid.
Understanding the Participant Demographics
The study included a robust cohort of 130 participants, demonstrating mean scores indicative of mild-to-moderate cognitive impairment, key elements relevant to DLB. This suggests that the fluctuations in attention observed align with recognized clinical benchmarks for diagnosing DLB. In addition, the majority of participants exhibited mild movement impairment, further validating their condition.
As explained by Anthony Caggiano, M.D., Ph.D., Cognition’s Chief Medical Officer and Head of Research and Development, the characteristics observed in this study resonate with findings in previous research dedicated to DLB.
Detailed Overview of Baseline Characteristics
The baseline characteristics gleaned from the poster presented at CTAD were as follows:
- Mean Age: 72.8 years
- Gender Distribution: 81.5% male
- Race: 91.5% white
- Mean MMSE Score: 24.0
- Mean MoCA Score: 18.4
- Mean CAF Score: 5.9
- Mean ESS Score: 8.4
- Mean MDS-UPDRS Part III Score: 27.7
- Mean ADCS-ADL Score: 62.5
These statistics help paint a comprehensive picture of how DLB affects participants and align closely with other studies aiming to identify effective treatment pathways.
Context on Dementia with Lewy Bodies
DLB is noted as the second most common form of dementia, impacting approximately 1.4 million individuals in the United States alone. This degenerative condition results from the pathological buildup of the protein ?-synuclein, forming aggregates known as Lewy bodies within neurons. Patients may present a range of symptoms including fluctuating consciousness, hallucinations, delusions, and movement disorders.
As Lisa Ricciardi, Cognition’s president and CEO, remarked, understanding these characteristics in relation to other studies highlights the importance of continued research in this area.
The SHIMMER Study's Approach
The SHIMMER study is a meticulously designed double-blind, placebo-controlled clinical trial involving 130 adults diagnosed with mild-to-moderate DLB. Participants are randomly administered either a placebo or one of two doses of CT1812 (100 mg or 300 mg) for a duration of six months. This study method allows for reliable assessments of cognitive performance via various established metrics such as the MoCA and MMSE.
The study is receiving significant funding support from the National Institutes of Health (NIH), specifically from the National Institute on Aging, with a grant exceeding $30 million. Collaborations are in place with some esteemed centers specializing in Lewy body dementia to ensure comprehensive data collection and participant care.
Exploring the Role of CT1812
CT1812 represents a forward-thinking approach to treatment, characterized as an experimental small molecule that carefully targets the sigma-2 receptor complex while overcoming the blood-brain barrier. Preliminary studies exhibit promising results indicating its ability to displace harmful A? oligomers, which are implicated in Alzheimer's disease and cognitive decline.
Cognition Therapeutics is actively recruiting participants for their related studies in Alzheimer’s disease and other degenerative conditions, demonstrating commitment to advancing innovative therapeutic strategies.
A Glimpse into Cognition Therapeutics
Cognition Therapeutics, Inc. is dedicated to discovering and establishing powerful new treatments aimed at age-related degenerative disorders affecting both the central nervous system and retina. The company’s innovative approach with CT1812 and their extensive pipeline for ?-2 receptor modulation highlights a unique position in the potential treatment landscape for these challenging diseases.
Frequently Asked Questions
What is the SHIMMER study about?
The SHIMMER study is a Phase 2 clinical trial aimed at evaluating the efficacy of CT1812 in participants with mild-to-moderate dementia with Lewy bodies.
How many participants are involved in the SHIMMER study?
The study includes 130 participants who are being assessed over the course of the trial.
What are some common symptoms associated with DLB?
DLB symptoms include fluctuations in attention, hallucinations, movement disorders, and changes in cognitive abilities.
What approach does CT1812 take for treatment?
CT1812 is designed as a small molecule oligomer antagonist, targeting the sigma-2 receptor to alleviate cognitive impairment caused by toxic protein aggregation.
Where can I learn more about Cognition Therapeutics?
Further information about Cognition Therapeutics, including their clinical programs, can be found on their official website.
